Intelence

USDailyMed:Etravirine AU:B1 J05AG04(WHO) AU:S4(Prescription only)CA:Schedule VIUK:POM(Prescription only)US:℞-onlyEU:Rx-only 4-[6-Amino-5-bromo-2-[(4-cyanophenyl)amino] pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile 269055-15-4Y 193962 DB06414N 168313Y 0C50HW4FO1 D04112Y ChEMBL308954Y 105156 65B (PDBe,RCSB PDB) DTXSID30181412 Interactive image N#Cc3cc(c(Oc1nc(nc(c1Br)N)Nc2ccc(C#N)cc2)c(c3)C)C InChI=1S/C20H15BrN6O/c1-11-7-14(10-23)8-12(2)17(11)28-19-16(21)18(24)26-20(27-19)25-15-5-3-13(9-22)4-6-15/h3-8H,1-2H3,(H3,24,25,26,27)YKey:PYGWGZALEOIKDF-UHFFFAOYSA-NY Etravirine(ETR), sold under the brand nameIntelenceis anantiretroviral medicationused for the treatment ofHIV.Etravirine is a human immunodeficiency virus type 1 (HIV-1)non-nucleoside reverse transcriptase inhibitor(NNRTI).Unlike agents in the class, resistance to other NNRTIs does not seem to confer resistance to etravirine.Etravirine is marketed byJanssen, asubsidiaryofJohnson & Johnson. In January 2008, the USFood and Drug Administration(FDA) approved its use for people with established resistance to other drugs, making it the 30th anti-HIV drug approved in the United States and the first to be approved in 2008.It was also approved for use in Canada in April 2008. Etravirine is licensed in the United States, Canada, Israel, Russia, Australia, New Zealand, and the European Union,and is under regulatory review in Switzerland.